CN109136268A - A kind of construction method of LRFF cell - Google Patents

A kind of construction method of LRFF cell Download PDF

Info

Publication number
CN109136268A
CN109136268A CN201811153227.4A CN201811153227A CN109136268A CN 109136268 A CN109136268 A CN 109136268A CN 201811153227 A CN201811153227 A CN 201811153227A CN 109136268 A CN109136268 A CN 109136268A
Authority
CN
China
Prior art keywords
cell
lrff
polypeptide
epitope
construction method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201811153227.4A
Other languages
Chinese (zh)
Inventor
焦顺昌
张嵘
张天赋
周子珊
解佳森
王海燕
吴子明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Dingcheng Taiyuan Biotechnology Co Ltd
Original Assignee
Beijing Dingcheng Taiyuan Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Dingcheng Taiyuan Biotechnology Co Ltd filed Critical Beijing Dingcheng Taiyuan Biotechnology Co Ltd
Priority to CN201811153227.4A priority Critical patent/CN109136268A/en
Publication of CN109136268A publication Critical patent/CN109136268A/en
Priority to CN201910443232.7A priority patent/CN110093371B/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

The present invention carries out ctDNA sequencing using peripheral blood in patients or tumor tissues carry out full exon sequencing, filters out mutational site and carries out Epitope prediction, connects and synthesize mutant polypeptide expressing gene sequence；Slow virus carrier is constructed simultaneously, pack slow virus, transfect APC cell, complete the transformation of specificity LV cell, the PBMC separated in vitro with from peripheral blood is co-cultured, and filters out effective accurate polypeptide, the second Secondary Shocks stimulated by accurate polypeptide, general T cell is transformed into the LRFF cell for more precisely killing ability, improves T cell to the lethality of tumour cell.The LRFF cell that invention provides can be widely applied to individuation and precisely treat entity tumor.

Description

A kind of construction method of LRFF cell
Technical field
The invention belongs to field of biotechnology, and in particular to a kind of construction method of LRFF cell.
Background technique
Currently, existing LAK, DC, CIK, DC-CIK cell and method are basic in terms of the specific active immunotherapy of tumour It is proved to be invalid, and the cell technologies such as NK, CAR-NK, TIL need maturation, CAR-T cell is in safety and solid tumor It is also defective in treatment.The prior art generally passes through transformation DC cell, generates specific killing by DC submission T cell.Some experiments It is attempting to carry out transfection submission T cell, the specific killing of inducing T cell as the method for carrier with virus in room.We were also once PBMC, inducing T cell are directly stimulated with mutation mixed polypeptide.
The above treatment method has limitation, especially external evoked DC cell and DC cell loading tumour antigen technology reason It is more by upper research, but there are many more problems in the specific implementation process, lack specific, tumour cell occurrence and development key Signal transduction pathway relevant molecule is as inducing antigen, because tumour antigen is unknown and the immunosuppressive obstacle of tumor microenvironment, Make to realize that specific cell targeting immunization therapy is difficult to smoothly implement.Although not having in addition, what is had has carried out antigen in vitro impact There are progress external cultivation and amplification in vitro altogether, allows more thin specific cell directly facing complicated tumour immunity micro-loop Border, therefore, it is difficult to play expected effect.Although also have can also external submission and total cultivation, the single (MAGE- of target spot 3) it, only works to individual cancer kinds such as non-small cell lung cancer.Transfection submission is carried out although also having and attempting the method that slow virus is carrier, But safety, convenience are not so good as polypeptide mode.And the direct stimulation of polypeptide is simply mixed, although simple and convenient, efficiency is lower.
Above scheme is accurately and effectively analyzed general lack of to patient's antigen, and more efficient way should should consider to pacify Full property problem, takes into account antigen submission efficiency again, can be only achieved the purpose precisely treated in this way.
Summary of the invention
The present invention carries out ctDNA sequencing using peripheral blood in patients or tumor tissues carry out full exon sequencing, filters out prominent Displacement point carries out Epitope prediction, connects and synthesizes mutant polypeptide expressing gene sequence；Slow virus carrier is constructed simultaneously, is packed Slow virus transfects APC cell, completes the transformation of specificity LV cell, and the PBMC separated in vitro with from peripheral blood is co-cultured, sieve Effective accurate polypeptide is selected, the second Secondary Shocks stimulated by accurate polypeptide, general T cell, which is transformed into, to be had more precisely The LRFF cell of killing ability improves T cell to the lethality of tumour cell.
LRFF cell provided by the invention can be widely applied to individuation and precisely treat entity tumor.
Explanation for specific term:
L: slow-virus transfection technology
R: accurate polypeptide secondary pulse technology
FF: mixed polypeptide technology
Such as: LRFF cell is finally obtained via above-mentioned L, R, FF items technical solution or technological means transformation Cell.
LRFF cell modification scheme is summarized as follows:
1, Epitope prediction
1) using source of people peripheral blood carry out ctDNA sequencing or commercially available engineering cell system (such as H1299, H226, H358, H1563, H2228, A549, Renca, LLC Lewis lung cancer cells, CRL-6323B16F1, CRL-2539 4T1, U14 are small Mouse cervical cancer cell, the small glioma cell of BV-2 mouse, G422 mouse glioma cell etc.) carry out MHC type detection Detection RNA mutation is sequenced with full exon；
2) MHC type and gene mutation information prediction epitope are utilized: centered on the amino acid sites of mutation, to two Side extends 8 amino acid, using the polypeptide of 17 amino acid of this section as potentially antigenic epitope；
3) IC50 that potentially antigenic epitope is analyzed using forecasting software, thinks this potentially antigenic table if IC50 < 1000nM Position is epitope；
2, polypeptide connects
1) IC50 that any epitope is connected two-by-two at rear joint is analyzed using aforementioned software, when IC50 >=1000nM recognizes To be weak immunogene, can connect；It is considered strongly immunogenic when IC50 < 1000nM, cannot connects；
2) according to the above results, the epitope of weak immunogene is linked together, joint IC50 is higher than two sides The IC50 of epitope (namely joint, which avoids generating as far as possible, combines by force antigen)；
3, the gene order of composite coding polypeptide
1) polypeptide after connection is reduced to nucleic acid sequence, and carries out codon optimization；
2) gene order of solid-phase synthesis synthetic antigen epitope peptide is used；Or it is synthesized by technical service company；
4, slow virus is packed
After the slow virus expression plasmid for the gene order building expression epitope peptide that upper step is synthesized, slow virus packet is carried out Dress；
5, it transfects antigen presenting cell (APC) and is co-cultured with PBMC
1) using the slow-virus transfection antigen presenting cell of expression epitope peptide, (including but not limited to: peripheral blood is single Nucleus, Dendritic Cells, neutrophil leucocyte, bone-marrow-derived lymphocyte, macrophage)；
2) APC that processing is completed is collected, is mixed and is co-cultured with the ratio of APC:PBMC=1:5-20, obtain effector cell；
6, effective accurate polypeptide is screened, and stimulates T cell again using accurate polypeptide
1) T cell of above scheme acquisition is collected by centrifugation, polypeptide directly stimulates T cell to screen accurate polypeptide as antigen:
2) positive control: T cell+100ng/mL OKT3 is set；Negative control: T cell+1640+10%FBS+200U/ mL IL2；
3) accurate polypeptide judgment criteria:
A. positive control and negative control are normal, then illustrate that this data is credible；
B. it is effective accurate polypeptide that experimental group, which is noticeably greater than negative control group,；
4) the accurate polypeptide secondary pulse T cell to filter out, filters out the specificity that can identify the accurate polypeptide Cell is to get LRFF cell；
7, building specific antigen expression target cell and tumor model survival assay.
Beneficial effects of the present invention:
1. novel specific LRFF cell of the present invention finds out accurate polypeptide and carries out secondary stimulus on the basis of LV cell, Having better solved patient's immunocyte cannot accurately identify and the problem of killing tumor cell, at the same compensate for LV cell and The deficiency of RFF cell, the killing-efficiency of RFF are not so good as LRFF cell, and the specificity of LV cell is not so good as LRFF cell.
2. tumour antigen is mutant antigen, different from other tissues, target spot specificity is strong, is not susceptible to undershooting-effect, pacifies Quan Xinggao；
3. the specific cell ratio obtained is high, the specific cell of tumour antigen usually can be identified, in point of PBMC Cloth be 0.5% hereinafter, by LRFF retrofit scheme cell, identify that specific T-cells (TCR+) ratio of tumour antigen is 10% or more.
Detailed description of the invention
Fig. 1: slow-virus transfection APC Efficiency testing；Wherein, 1A: control group, 1B: transfection group.
The detection of Fig. 2: LRFF cell typing.
Fig. 3: the screening of accurate polypeptide.
Fig. 4: flow cytometer detection specific T-cells ratio；Wherein, 4A: control group, 4B:LRFF scheme.
Fig. 5: LDH release detection cell killing efficiency.
The release of Fig. 6: ELISA detection cell factor IFN-γ.
Fig. 7: animal lotus knurl model survivorship curve.
Specific embodiment
The present invention is described below by specific embodiment.Unless stated otherwise, technological means used in the present invention It is method known in those skilled in the art.In addition, embodiment is interpreted as illustrative, it is not intended to limit the present invention Range, the spirit and scope of the invention are limited only by the claims that follow.To those skilled in the art, without departing substantially from this Under the premise of invention spirit and scope, to the various changes or change of material component and dosage progress in these embodiments It belongs to the scope of protection of the present invention.
Details are as follows for technical solution:
1, Epitope prediction
1) ctDNA sequencing is carried out using peripheral blood from patients with lung cancer and HLA parting detects；
2) sequencing information is analyzed using software: by ctDNA sequencing result compared with the genome of normal cell, sieve Select mutational site；
3) centered on the amino acid sites of mutation, extend 8 amino acid to two sides, by the polypeptide of 17 amino acid of this section As potentially antigenic epitope；
4) using forecasting software analyze potentially antigenic epitope IC50 (recommend software: NetMHCpan 3.0, PickPocket, artificial neural networks (ANN)), this potentially antigenic table is thought if IC50 < 1000nM Position is epitope.
2, polypeptide connects
1) IC50 that any epitope is connected two-by-two at rear joint is analyzed using aforementioned software, when IC50 >=1000nM recognizes To be weak immunogene, can connect；It is considered strongly immunogenic when IC50 < 1000nM, cannot connects and (be considered as 3 herein The IC50 calculated result of forecasting software can just be considered weak immunogene as IC50 >=1000nM that >=2 software calculates, when It can just be considered strongly immunogenic when the IC50 < 1000nM that >=2 software calculates)；
2) according to the above results, epitope is linked together, joint IC50 is higher than two sides epitope IC50 (namely joint, which avoids generating as far as possible, combines by force antigen)；Weak immunogene peptide will be exempted from by force as link peptide when necessary Epidemic focus peptide interval；Or patient's self amino acid is added to joint, for reducing a possibility that generating strong antigen.
3, the gene order of composite coding polypeptide
1) polypeptide after connection is reduced to nucleic acid sequence, and carries out codon optimization；
If the nucleic acid sequence shorter (< 100bp) after the completion of connection can suitably repeat amino acid sequence, but It is, it should be noted that inverted repeat in gene order, directly repetition and mirror image should be avoided to repeat sequence as far as possible when being reduced into gene order The appearance of column
2) gene order (being synthesized by technical service company) of solid-phase synthesis synthetic antigen epitope peptide is used.
4, slow virus is packed
1) the epitope peptide gene sequence of synthesis is cloned into pCDH-MSCV-MCS-EF1-copGFP plasmid, is constructed Express the slow virus expression plasmid of epitope peptide；
2) slow virus is packed:
A. recovery 293T cell is packed after passing for two generations for slow virus；
B. cell transfecting: (T175 culture bottle)
A 15ml centrifuge tube (labeled as A) is taken, 4mL is lightly added in 400 μ L Lipofectamine 2000 It in DMEM, lightly mixes, is stored at room temperature culture 5min；
Two 15mL centrifuge tubes (labeled as B and C, B is control group, and C is experimental group) is separately taken, following reagent and gently is added Ground mixes, and is stored at room temperature culture 5min；
A pipe liquid is averagely transferred in B pipe and C pipe, is lightly mixed, culture 20min is stored at room temperature.
Culture medium old in T175 is poured out, cell is washed one time using PBS, changes new 25mL DMEM into (without antibiosis Element and serum), A, B or A, C mixed liquor is lightly added, gently shakes up, is placed in 37 DEG C, is cultivated in 5%CO2 incubator；
After transfecting 6h, the culture medium containing transfection composite is sucked, is changed to the fresh culture of 37 DEG C of preheatings；Culture 48h, and collect；
3) slow virus concentration and titer determination:
After slow virus is packed successfully, slow virus supernatant is collected, 4 DEG C, 4000g is centrifuged 10min；It is filtered with 0.45 μm of filter Supernatant removes cell fragment；According to vial supernatant: the mixing of concentrated reagent=5:1 ratio, 4 DEG C of placement 2h or overnight； By the mixed liquor being incubated in 4 DEG C, 4000g is centrifuged 30min, i.e., visible tube bottom has rice white precipitating；Carefully supernatant is removed (to be sure not Touch sediment)；The DMEM or PBS of appropriate volume is added, gently sediment is resuspended in piping and druming；Packing virus on demand, -80 DEG C save (note: slow virus never multigelation, every freeze thawing is primary, and lentivirus titers will decline 10%-20%)；
Measurement the previous day is diluted to 5 × 10 after counting the good 293H cell dissociation of growth conditions496 holes are added in/mL Plate, 100 holes μ L/ prepare 8-10 hole for each virus.37 DEG C are put into, is cultivated in 5%CO2 incubator
It takes a certain amount of virus liquid infection cell: doing 10 times of gradient dilutions in EP pipe.Dilution process is as follows: every kind of virus Prepare 10 1.5mL EP pipes, every pipe is added 90 μ L culture solutions, 10 μ L virus stock solution useds are added into first pipe, are denoted as 100；It is mixed After even, draw 10 μ L and second pipe mixing is added, be denoted as 10-1；And so on (100-10-8), 10 μ are added in corresponding cell hole Virus liquid that L has diluted simultaneously marks, and observes result after cultivating 48-72h；
Titre calculates: fluorescent technique method can be used to measure titre the slow virus with fluorescent marker；In fluorescence microscopy Under the microscope as a result, and count most latter two have fluorescence fluorecyte clone number, it is assumed that be X and Y, then titre (TU/mL)= The content (μ L) of the virus liquid in the hole (X+Y × 10) × 1000/2/X.
5, slow-virus transfection antigen presenting cell (APC) and with PBMC co-culture
1) it is prepared using RPMI-1640 and contains 300U/mL rIL-2, the full cell culture medium of 10%FBS is denoted as RPMI- 10-IL-2；APC cell concentration is adjusted to 1 × 10 using RPMI-10-IL-26/mL；Use the slow disease of expression epitope peptide With MOI=5-20 infection APC, (including but not limited to: peripheral blood mononuclear cells, Dendritic Cells, neutrophil leucocyte, B drench poison Bar cell, macrophage)；It is put into 37 DEG C of culture 72h；
4) APC that processing is completed is collected, is mixed with the ratio of APC:PBMC=1:5-20, PBMC is about 5 × 107, it is added 50mL OKM100 culture medium is into T75 culture bottle；It is put into 30-37 DEG C of cell incubator and cultivates 14 days, i.e. acquisition LFF scheme Effector cell.
6, effective accurate polypeptide is screened
Polypeptide is as the direct accurate polypeptide of stimulating effect cell screening of antigen:
1) the above LFF Protocols Cell is collected by centrifugation, 1500rpm is centrifuged 5min and collects T cell, and 10mL PBS is added and is resuspended carefully Born of the same parents simultaneously count, and 1500rpm is centrifuged 5min, collect T cell with 1640+10%FBS+200U/mL IL2 resuspension, counting is adjusted to 1 ×106cells/mL；
2) T cell is divided into 96 hole flat undersides with the volley of rifle fire, 200 holes μ L/, cell number is 2 × 105cells；Add respectively again Enter the mutant polypeptide of 10 μ L 1mg/mL, final concentration of 50 μ g/mL, 3 multiple holes are arranged in every polypeptide；
3) positive control: T cell+100ng/mL OKT3 is set；Negative control: T cell+1640+10%FBS+200U/ mL IL2；
4) 37 DEG C, 5%CO2After stimulation for 24 hours, 1500rpm is centrifuged 10min, shifts 140 μ L supernatants into 96 new orifice plates；
5) 96 orifice plates are centrifuged again, 1500rpm 10min, take sample carry out ELISA detection (or by sample as- 80 DEG C of preservations)；
Detect the ELISA system of IFN-γ:
1) testing the ELISA kit that can be used for detecting IFN-γ has Biolegend:LEGEND MAX Human at present IFN-γ ELISA Kit with Pre-coated Plates (article No.: 430107) He Dake are as follows: Human IFN-γ ELISA Kit (article No.: DKW12-1000-096), is please operated in strict accordance with shop instruction；
2) the manual wrapper sheet system of ELISA (15 blocks of plates): Human IFN-gamma DuoSet 15plate (article No.: DY285B) × 2 (article No.: DY008) × 31, DuoSet ELISAAncillary Reagent Kit；
Accurate polypeptide judgment criteria:
1) positive control and negative control are normal, then illustrate that this data is credible；
2) when experimental group is noticeably greater than negative control, illustrate that polypeptide is effective accurate polypeptide.
7, the accurate polypeptide secondary pulse T cell to filter out
1) when PBMC is cultivated with step 5 to the 2nd~14 day, 2 × 10 are taken7Effector cell, final concentration of 10 μ g/ is added The accurate polypeptide of the μ of mL~100 g/mL impacts 1-4h；
2) it after impacting 4h, is transferred in the 6 orifice plates of the pre- wrapper sheet of OKM25 or T25cm2Culture bottle mends OKM100+12%FBS, 37 DEG C of 5%CO2Culture, according to cell growth status, is transferred in T75 culture bottle, and holding cell density as far as possible is 1 × 106 cells/mL；
3) when entering in T175 culture bottle, culture medium OKM200+5%FBS, culture can be obtained precisely more for 10~14 days The T cell that peptide secondary pulse obtains；
8, building specific antigen expression target cell and tumor model survival assay
1) building can be with the slow virus carrier of the accurate polypeptide (specific antigen) of expression screening.
2) specific antigen expression slow virus carrier is packaged into lentiviral particle, the infection suitable tumour of HLA distribution type is thin Born of the same parents stablize and are overexpressed specific antigen, flow cytometer detection expression and expression intensity.
3) stablize the tumor cell line inoculation NGS mouse for being overexpressed specific antigen peptide, do dystopy tumor-bearing model.It will 5×105The tumour cell of expression specificity antigen is suspended from 100 μ l physiological saline, is subcutaneously injected respectively to 30 NSG mouse Right side side of body rib portion is subcutaneous, while mouse being numbered.
4) in tumour growth to 100-120mm3Grouping feeds back cell when left and right, according to gross tumor volume size, by animal mould Type is randomly divided into three groups, and every group of 5-6 mouse, one group is given placebo physiological saline, gives for one group and does not carry out any heredity The T cell (control group) 1 × 10 of operation7, one group is given LRFF cell 1 × 107, second, which is carried out, after injecting cell 7 days for the first time infuses It penetrates, third time injection cell, is observed continuously 60 days after 7 days, counts survival data, draws survivorship curve.
Test result:
1, mutational site and Epitope prediction
Table 1 is the mutational site and Epitope prediction result that sequencing detects；
1 Epitope prediction of table
2, slow-virus transfection APC Efficiency testing
1) it is prepared using RPMI-1640 and contains 300U/mL rIL-2, the full cell culture medium of 10%FBS is denoted as RPMI- 10-IL-2；APC cell concentration is adjusted to 1 × 10 using RPMI-10-IL-26/mL；Use the slow disease of expression epitope peptide With MOI=5-20 infection APC, (including but not limited to: peripheral blood mononuclear cells, Dendritic Cells, neutrophil leucocyte, B drench poison Bar cell, macrophage)；It is put into 37 DEG C of culture 72h；
2) using GFP positive ratio (as shown in Figure 1) in flow cytomery APC.
3, LFF cell typing detects
After LFF Protocols Cell culture, the parting detection of CD4+, CD8+ cell is carried out, as a result as shown in Figure 2: CD8+T Cell is that 89.1%, CD4+T cell is 8.11%.
4, with the accurate polypeptide of LFF cell screening
The T cell for being stimulated culture respectively with 12 polypeptides is detected effective polypeptide, tied by detecting the secretion of IFN-γ Fruit is as shown in Figure 3: burst size > negative control burst size of IFN-γ caused by No. 3 and No. 7 polypeptides, belongs to effectively precisely more Peptide.
5, to the identification and sorting of the T cell of accurate polypeptid specificity
With No. 3 of screening and No. 7 polypeptides, LFF Protocols Cell is stimulated, it is thin with T of the flow cytometer detection to accurate polypeptid specificity Born of the same parents' ratio, as a result as shown in figure 4, FL1+ is specific T-cells: LRFF Protocols Cell, No. 3 and the caused release of No. 7 polypeptides The cell proportion of IFN-γ, hence it is evident that higher than not having irritant cell (control group), illustrate, LRFF scheme can be obtained to accurate The specific T-cells of polypeptide；
6, lethal effect of the LRFF cell to target cell
Carry out the detection of killing-efficiency to the target cell in mutant antigen epitope source with control cell and LRFF cell respectively, Using non-treated cell as control (Mock), effect target ratio is set as 40:1, as a result as shown in figure 5, compared with the control group, LRFF Cell has stronger fragmentation effect to target cell.
7, the detection of LRFF cell cytokine release
When tumour cell and effector cell co-culture, due to effector cell, can with mutant antigen on tumor cell, because This, can generate a series of cell factor, and IFN-γ is one of most important cell factor in antitumor action, Fig. 6 LRFF When cell and tumour cell 1:1 are co-cultured, the detection of the IFN-γ of release, the results showed that generated with effector cell itself IFN-γ compares (T cells only), and after co-culturing with tumour cell, LRFF cell can produce this result of a large amount of IFN-γ Consistent with killing experiments result to illustrate: the specific T-cells that accurate polypeptide stimulates again can more effectively improve antitumor energy Power.
8, building specific antigen expression target cell and tumor model survival assay
Specific antigen expression tumour target cell system is successfully constructed, establishes tumor-bearing model, as the result is shown (Fig. 7), The existence of LRFF cells against tumor tumor-bearing mice, which improves to have, significantly affects effect.
9, clinical case:
Certain male: 57 years old
Medical diagnosis on disease: left kidney neoplasms；
First course for the treatment of: monthly LRFF cell, quantity 1 × 109A cell, totally 2 times；
Second course for the treatment of: every half a year LRFF cell, quantity 1 × 109A cell, totally 2 times；
After administration, 22 months Progression free survivals；
Other cases:
Patient code Medical diagnosis on disease The Progression free survival time
1 Sdenocarcinoma of stomach hepatic metastases 2015.4- so far
2 Gastric cancer 2015.4- so far
3 Lung cancer 2015.5- so far
4 Adenocarcinoma of lung 2015.5- so far
5 Adenocarcinoma of lung 2015.5- so far
6 The cancer of the esophagus 2015.6- so far
Note: containing for " so far " is meant " on the day before the applying date ".

Claims (4)

1. a kind of construction method of LRFF cell, which is characterized in that 1) construction method includes the following steps: using outside source of people All blood carries out ctDNA sequencing or tumor tissues carry out full exon sequencing, filters out mutational site；2) it is carried out according to mutational site Epitope prediction synthesizes the gene order of mutant polypeptide；3) slow virus carrier of building expression mutant polypeptide packs slow disease Poison；4) it transfects antigen presenting cell and is co-cultured with PBMC, obtain LFF cell；4) mutant polypeptide is as antigenic stimulus institute LFF cell is stated, effective accurate polypeptide is filtered out；5) it stimulates the LFF cell again using the accurate polypeptide as antigen, sieves The specific cell that can identify the accurate polypeptide is selected to get LRFF cell.
2. the construction method of LRFF cell as described in claim 1, which is characterized in that the source of people peripheral blood is also possible to city Sell engineering cell system.
3. the construction method of LRFF cell as described in claim 1, which is characterized in that the Epitope prediction is to be mutated Amino acid sites centered on, respectively extend 8 amino acid to two sides, using the polypeptide of 17 amino acid of this section as potentially antigenic table Position；The IC50 that potentially antigenic epitope is analyzed using forecasting software thinks that this potentially antigenic epitope is anti-if IC50 < 1000nM Former epitope.
4. the construction method of LRFF cell as described in claim 1, which is characterized in that the antigen presenting cell includes: outer All blood mononuclear cells, Dendritic Cells, neutrophil leucocyte, bone-marrow-derived lymphocyte, macrophage.
CN201811153227.4A 2018-09-30 2018-09-30 A kind of construction method of LRFF cell Withdrawn CN109136268A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201811153227.4A CN109136268A (en) 2018-09-30 2018-09-30 A kind of construction method of LRFF cell
CN201910443232.7A CN110093371B (en) 2018-09-30 2019-05-24 Construction method of LRFF cell

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811153227.4A CN109136268A (en) 2018-09-30 2018-09-30 A kind of construction method of LRFF cell

Publications (1)

Publication Number Publication Date
CN109136268A true CN109136268A (en) 2019-01-04

Family

ID=64813682

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811153227.4A Withdrawn CN109136268A (en) 2018-09-30 2018-09-30 A kind of construction method of LRFF cell
CN201910443232.7A Active CN110093371B (en) 2018-09-30 2019-05-24 Construction method of LRFF cell

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910443232.7A Active CN110093371B (en) 2018-09-30 2019-05-24 Construction method of LRFF cell

Country Status (1)

Country Link
CN (2) CN109136268A (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104662171B (en) * 2012-07-12 2018-07-13 普瑟姆尼股份有限公司 Individualized cancer vaccine and adoptive immunity cell therapy
CN103242448B (en) * 2013-05-27 2015-01-14 郑州大学 Full-humanized anti-PD-1 monoclonal antibody and preparation method and application thereof
EP3084435A1 (en) * 2013-12-19 2016-10-26 Opexa Therapeutics, Inc. Methods of t cell epitope profiling, making t cell compositions, and treating diseases
CN104099297A (en) * 2014-07-24 2014-10-15 南通大学附属医院 Polygene transfection tumor cell strain and fusion vaccine thereof, as well as preparation methods
WO2016053338A1 (en) * 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation

Also Published As

Publication number Publication date
CN110093371B (en) 2021-06-18
CN110093371A (en) 2019-08-06

Similar Documents

Publication Publication Date Title
CN110499297A (en) A kind of novel oncolytic virus and its preparation method and application
CN111315873A (en) Isolated recombinant oncolytic poxvirus, pharmaceutical compositions and use thereof in a medicament for the treatment of tumors and/or cancers
CN109553686A (en) The novel regulatable double Chimeric antigen receptor T cells of one kind and its construction method and application
CN106544365A (en) A kind of preparation method and application of the CIK of the anti-CD19 Chimeric antigen receptors modification of people
CN110093376A (en) A kind of construction method of LRFFT1 cell
CN105367661B (en) Chimeric antigen receptor and its gene and recombinant expression carrier, the NKT cell of engineering HER1 targeting and its application
CN109679917A (en) A kind of LRFFT2 cell
CN109294997A (en) A kind of LRFFT1 cell
CN109136268A (en) A kind of construction method of LRFF cell
CN109337873A (en) A kind of LRFF cell
CN109136278A (en) A kind of MRFFT1 cell
CN109136277A (en) A kind of construction method of LRFFT2 cell
CN110157745A (en) A kind of construction method of HAFFT1 cell
CN109294982A (en) A kind of RFF2 cell
CN110241088A (en) A kind of construction method of mice pancreatic cancerous cell line and syngenetic graft tumor model
CN108823247A (en) A kind of humanization CD-19 Chimeric antigen receptor T lymphocyte carrier and its application
CN109295097A (en) A kind of MRFFT2 cell
CN109136279A (en) A kind of construction method of MRFFT2 cell
CN109136281A (en) A kind of construction method of MRFFT1 cell
CN109294983A (en) A kind of LFF2 cell
CN109400712A (en) The preparation method and applications of third generation LMP1 CAR-T cell
CN109679916A (en) A kind of LFF1 cell
CN109055317A (en) A kind of AFP combines CIK immunocyte and its preparation method and application with the DC of the dual anti-protogene modification of HBsAg
CN110129276A (en) A kind of construction method of LFF1 cell
CN110093317A (en) A kind of construction method of LFF2 cell

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20190104